Innospec closed the first half as a three-segment specialty chemical house whose cash engine still funds a debt-free balance sheet while two of the three books remain mid-repair. Fuel Specialties carried the franchise through a storm-hit first quarter and then a rebound second quarter that lifted group sales to $491.4 million. Operating income in that June quarter advanced sixteen percent on the year-earlier print. The investment case is not a growth story in the classical sense; it is a question of whether plant restoration and mix repair convert an already liquid balance sheet into a higher-quality earnings stream.
The January winter storm shut the North Carolina Performance Chemicals plants and cut that segment's first-quarter operating income nearly in half. June then printed a recovery, with Performance Chemicals operating income at $16.4 million, up fifteen percent. Oilfield Services operating income rose forty percent on drag-reducing-agent mix. The franchise still has to prove that those sequential gains survive a third quarter that management already flagged for fuel-additive margin lag.
Full-year twenty twenty-five sales of $1.78 billion already showed the same split, with Fuel Specialties carrying the profit load while Oilfield Services and Performance Chemicals compressed. Net income of $116.6 million looked like a rebound only because the prior year absorbed a $155.6 million pension settlement. Operating cash flow fell for a third straight year, to $138.3 million. Cash conversion, not the headline earnings rebound, is the figure that still has to heal.
Net cash stood at $250.2 million at the June close with nothing drawn on the revolving facility. The board lifted the semi-annual dividend to $0.92 and reset a $75 million repurchase authorization. Management expects further second-half operating-income gains in Performance Chemicals and Oilfield Services, and a steady Fuel Specialties print. The autumn reporting cycle is the first clean test of whether cash generation follows the income statement higher.